Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Accured Expenses (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Change in Accured Expenses readings, the most recent being -$861000.0 for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 91.17% to -$861000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$664000.0, a 111.96% decrease, with the full-year FY2025 number at -$664000.0, down 111.96% from a year prior.
  • Change in Accured Expenses hit -$861000.0 in Q4 2025 for Tandem Diabetes Care, down from $12.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $15.8 million in Q3 2024 to a low of -$28.5 million in Q4 2022.
  • Median Change in Accured Expenses over the past 5 years was $1.1 million (2024), compared with a mean of $1.3 million.
  • The widest YoY moves for Change in Accured Expenses: up 1048.34% in 2022, down 756.96% in 2022.
  • Tandem Diabetes Care's Change in Accured Expenses stood at $4.3 million in 2021, then crashed by 756.96% to -$28.5 million in 2022, then skyrocketed by 134.18% to $9.7 million in 2023, then tumbled by 200.09% to -$9.8 million in 2024, then soared by 91.17% to -$861000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were -$861000.0 (Q4 2025), $12.8 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.